JP2021512167A5 - - Google Patents
Info
- Publication number
- JP2021512167A5 JP2021512167A5 JP2020562100A JP2020562100A JP2021512167A5 JP 2021512167 A5 JP2021512167 A5 JP 2021512167A5 JP 2020562100 A JP2020562100 A JP 2020562100A JP 2020562100 A JP2020562100 A JP 2020562100A JP 2021512167 A5 JP2021512167 A5 JP 2021512167A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- heteroalkyl
- formula
- independently
- Prior art date
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862623845P | 2018-01-30 | 2018-01-30 | |
| US62/623,845 | 2018-01-30 | ||
| US201862653285P | 2018-04-05 | 2018-04-05 | |
| US62/653,285 | 2018-04-05 | ||
| US201862688309P | 2018-06-21 | 2018-06-21 | |
| US62/688,309 | 2018-06-21 | ||
| PCT/US2019/015733 WO2019152440A1 (en) | 2018-01-30 | 2019-01-29 | Methods and compounds for treating disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021512167A JP2021512167A (ja) | 2021-05-13 |
| JP2021512167A5 true JP2021512167A5 (https=) | 2022-02-07 |
| JPWO2019152440A5 JPWO2019152440A5 (https=) | 2022-02-07 |
Family
ID=67479898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020562100A Pending JP2021512167A (ja) | 2018-01-30 | 2019-01-29 | 障害を治療するための方法及び化合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11773085B2 (https=) |
| EP (1) | EP3746135A4 (https=) |
| JP (1) | JP2021512167A (https=) |
| CN (1) | CN112236172A (https=) |
| WO (1) | WO2019152440A1 (https=) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017087885A1 (en) | 2015-11-19 | 2017-05-26 | Dana-Farber Cancer Institute, Inc. | Methods of identifying compounds that interfere with erg-driven misguidance of baf complexes in tmprss2-erg driven prostate cancers |
| EP4717317A2 (en) | 2017-06-20 | 2026-04-01 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| EP3710002A4 (en) | 2017-11-16 | 2021-07-07 | C4 Therapeutics, Inc. | DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION |
| JP2021512167A (ja) | 2018-01-30 | 2021-05-13 | フォグホーン セラピューティクス インコーポレイテッドＦｏｇｈｏｒｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 障害を治療するための方法及び化合物 |
| WO2019152437A1 (en) | 2018-01-30 | 2019-08-08 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| JP2021519337A (ja) | 2018-03-26 | 2021-08-10 | シー４ セラピューティクス， インコーポレイテッド | Ｉｋａｒｏｓの分解のためのセレブロン結合剤 |
| CN119751456A (zh) | 2018-04-16 | 2025-04-04 | C4医药公司 | 螺环化合物 |
| JP2021527137A (ja) | 2018-06-13 | 2021-10-11 | アンフィスタ セラピューティクス リミテッド | Ｒｐｎ１１を標的化するための二機能性分子 |
| WO2020051235A1 (en) | 2018-09-04 | 2020-03-12 | C4 Therapeutics, Inc. | Compounds for the degradation of brd9 or mth1 |
| TW202028209A (zh) * | 2018-09-27 | 2020-08-01 | 大陸商重慶複創醫藥研究有限公司 | 作為RET激酶抑制劑的取代的咪唑[1,2-a]吡啶和[1,2,4]三唑[1,5-a]吡啶化合物 |
| WO2020081556A2 (en) * | 2018-10-17 | 2020-04-23 | Dana-Farber Cancer Institute, Inc. | Non-canonical swi/snf complex and uses thereof |
| WO2020081588A1 (en) | 2018-10-17 | 2020-04-23 | Dana-Farber Cancer Institute, Inc. | Swi/snf family chromatin remodeling complexes and uses thereof |
| CA3118752A1 (en) | 2018-11-09 | 2020-05-14 | Vivace Therapeutics, Inc. | Bicyclic compounds |
| CN120698983A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| EP3917517A4 (en) | 2019-01-29 | 2023-01-25 | Foghorn Therapeutics Inc. | CONNECTIONS AND USES THEREOF |
| US12384776B2 (en) | 2019-01-29 | 2025-08-12 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2020160100A1 (en) | 2019-01-29 | 2020-08-06 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| CN113874016A (zh) | 2019-01-29 | 2021-12-31 | 福宏治疗公司 | 化合物及其用途 |
| US20230066136A1 (en) | 2019-01-29 | 2023-03-02 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| HUE070525T2 (hu) | 2019-04-16 | 2025-06-28 | Vivace Therapeutics Inc | Biciklusos vegyületek |
| GB201905721D0 (en) | 2019-04-24 | 2019-06-05 | Univ Dundee | Compounds |
| WO2021022163A2 (en) | 2019-07-31 | 2021-02-04 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| CN112625036A (zh) * | 2019-10-08 | 2021-04-09 | 上海海和药物研究开发股份有限公司 | 一类具有brd4抑制活性的化合物、其制备方法及用途 |
| CA3167275A1 (en) | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| AU2021214767A1 (en) | 2020-01-29 | 2022-07-28 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| US12528825B2 (en) | 2020-01-29 | 2026-01-20 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| AU2021231898A1 (en) * | 2020-03-05 | 2022-10-27 | C4 Therapeutics, Inc. | Compounds for targeted degradation of BRD9 |
| US12383555B2 (en) | 2020-05-20 | 2025-08-12 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| US11787800B2 (en) | 2020-07-29 | 2023-10-17 | Foghorn Therapeutics Inc. | BRD9 degraders and uses thereof |
| AU2021321415A1 (en) * | 2020-08-07 | 2023-02-09 | Cornell University | Therapeutic composition of cure-pro compounds for targeted degradation of bet domain proteins, and methods of making and usage |
| JP2023536657A (ja) * | 2020-08-07 | 2023-08-28 | コーネル ユニバーシティー | タンパク質をｅ３リガーゼの媒介によって分解するための、治療上有用なｃｕｒｅ－ｐｒｏ分子、ならびにその作製方法及び使用方法 |
| JP2024509268A (ja) | 2021-03-09 | 2024-02-29 | フォグホーン セラピューティクス インコーポレイテッド | 結晶形、それらを含有する組成物、及びそれらの使用方法 |
| WO2023283263A1 (en) * | 2021-07-06 | 2023-01-12 | Foghorn Therapeutics Inc. | Citrate salt, pharmaceutical compositions, and methods of making and using the same |
| KR20240073960A (ko) * | 2021-10-29 | 2024-05-27 | 지앙수 카니온 파마수티컬 씨오., 엘티디. | 5-치환된 피리딘-2(1h)-케톤계 화합물 및 이의 용도 |
| JP2025523393A (ja) | 2022-06-06 | 2025-07-23 | シーフォー セラピューティクス， インコーポレイテッド | 二環式置換グルタルイミドセレブロンバインダー |
| CN119384408A (zh) | 2022-06-16 | 2025-01-28 | 安菲斯塔治疗有限责任公司 | 用于靶向蛋白降解的双功能分子 |
| EP4587126A1 (en) | 2022-09-13 | 2025-07-23 | Amphista Therapeutics Ltd | Compounds for targeted protein degradation |
| CN115944617B (zh) * | 2022-12-07 | 2025-02-11 | 浙江大学医学院附属儿童医院 | 一种十字花科蔬菜中天然存在的异硫氰酸苯乙酯的抗子宫内膜癌药物应用 |
| GB202319256D0 (en) | 2023-12-15 | 2024-01-31 | Amphista Therapeutics Ltd | Novel compounds for targeted protein degradation |
| WO2025191109A1 (en) | 2024-03-13 | 2025-09-18 | Amphista Therapeutics Limited | Combinations comprising brd9 bifunctional compounds and their use in the treatment of cancer |
| WO2026052822A1 (en) | 2024-09-06 | 2026-03-12 | Amphista Therapeutics Limited | Tetrahydroisoquinoline compounds for targeted protein degradation |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| WO2001059094A2 (en) | 2000-02-11 | 2001-08-16 | The Salk Institute For Biological Studies | Method of regulating transcription in a cell by altering remodeling of cromatin |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| CA2406864A1 (en) | 2000-02-24 | 2001-08-30 | Life Technologies Corporation | Simultaneous stimulation and concentration of cells |
| US20050079512A1 (en) | 2003-02-26 | 2005-04-14 | Emerson Beverly M. | Methods of modulating gene expression |
| DK2238982T3 (da) | 2003-06-27 | 2013-01-28 | Astellas Pharma Inc | Terapeutisk middel til blødt væv-sarcom |
| WO2009018018A2 (en) | 2007-07-31 | 2009-02-05 | University Of Utah Research Foundation | Animal model of synovial sarcoma |
| AU2013365926B9 (en) | 2012-12-21 | 2019-01-17 | Zenith Epigenetics Ltd. | Novel heterocyclic compounds as bromodomain inhibitors |
| US9410943B2 (en) | 2013-03-14 | 2016-08-09 | The Board Of Trustees Of The Leland Stanford Junior University | Methods, compositions and screens for therapeutics for the treatment of synovial sarcoma |
| EP3290407B1 (en) | 2013-10-18 | 2020-01-01 | Celgene Quanticel Research, Inc | Bromodomain inhibitors |
| JP6553632B2 (ja) | 2013-11-18 | 2019-07-31 | フォーマ セラピューティクス，インコーポレイテッド | Ｂｅｔブロモドメイン阻害剤としてのテトラヒドロキノリン組成物 |
| US20160058872A1 (en) | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| US9918243B2 (en) | 2015-02-05 | 2018-03-13 | Telefonaktiebolaget Lm Ericsson (Publ) | Measurement procedure under adaptive frequency separation |
| EP3265453B1 (en) | 2015-03-05 | 2022-06-29 | Boehringer Ingelheim International GmbH | New pyridinones and isoquinolinones as inhibitors of the bromodomain brd9 |
| AR104259A1 (es) | 2015-04-15 | 2017-07-05 | Celgene Quanticel Res Inc | Inhibidores de bromodominio |
| CN105838039B (zh) | 2016-01-11 | 2018-05-01 | 珠海万通化工有限公司 | 一种pbat树脂组合物 |
| WO2017197056A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| EP4491236A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| EP3454862B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| AU2017281903B2 (en) * | 2016-06-23 | 2020-12-24 | Dana-Farber Cancer Institute, Inc. | Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use |
| US10138827B2 (en) | 2017-01-04 | 2018-11-27 | Ford Global Technologies, Llc | Evaporative emissions system check valve monitor for a multi-path purge ejector system |
| CN108658972A (zh) | 2017-03-28 | 2018-10-16 | 中国海洋大学 | 一种取代内酰胺类化合物及其制备方法和用途 |
| EP4717317A2 (en) | 2017-06-20 | 2026-04-01 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| US20200206344A1 (en) | 2017-08-21 | 2020-07-02 | Dana-Farber Cancer Institute, Inc. | Methods for modulating the interaction between ews-fli1 and baf complexes |
| EP3710002A4 (en) | 2017-11-16 | 2021-07-07 | C4 Therapeutics, Inc. | DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION |
| JP2021512167A (ja) | 2018-01-30 | 2021-05-13 | フォグホーン セラピューティクス インコーポレイテッドＦｏｇｈｏｒｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 障害を治療するための方法及び化合物 |
| CN108690020A (zh) | 2018-07-04 | 2018-10-23 | 清华大学 | 一种靶向降解bet蛋白的化合物及其应用 |
| WO2020051235A1 (en) | 2018-09-04 | 2020-03-12 | C4 Therapeutics, Inc. | Compounds for the degradation of brd9 or mth1 |
| CN120698983A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| CN113874016A (zh) | 2019-01-29 | 2021-12-31 | 福宏治疗公司 | 化合物及其用途 |
| CR20220105A (es) | 2019-09-16 | 2022-06-13 | Novartis Ag | Degradadores bifuncionales de brd9 y sus métodos de uso |
| AU2021231898A1 (en) | 2020-03-05 | 2022-10-27 | C4 Therapeutics, Inc. | Compounds for targeted degradation of BRD9 |
-
2019
- 2019-01-29 JP JP2020562100A patent/JP2021512167A/ja active Pending
- 2019-01-29 CN CN201980023754.XA patent/CN112236172A/zh active Pending
- 2019-01-29 WO PCT/US2019/015733 patent/WO2019152440A1/en not_active Ceased
- 2019-01-29 EP EP19746772.3A patent/EP3746135A4/en not_active Withdrawn
-
2020
- 2020-07-29 US US16/942,021 patent/US11773085B2/en active Active
-
2023
- 2023-08-23 US US18/454,594 patent/US20240150328A1/en not_active Abandoned